Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Assets (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Assets for 7 consecutive years, with $688.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Assets rose 2.81% to $688.1 million in Q4 2025 year-over-year; TTM through Nov 2025 was $688.1 million, a 2.81% increase, with the full-year FY2025 number at $688.1 million, up 2.81% from a year prior.
  • Assets was $688.1 million for Q4 2025 at Nurix Therapeutics, up from $522.5 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $688.1 million in Q4 2025 to a low of $308.2 million in Q3 2023.
  • A 5-year average of $470.1 million and a median of $468.1 million in 2021 define the central range for Assets.
  • Peak YoY movement for Assets: crashed 32.9% in 2023, then surged 96.7% in 2025.
  • Nurix Therapeutics' Assets stood at $476.8 million in 2021, then decreased by 12.59% to $416.8 million in 2022, then fell by 14.68% to $355.6 million in 2023, then surged by 88.23% to $669.3 million in 2024, then increased by 2.81% to $688.1 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Assets are $688.1 million (Q4 2025), $522.5 million (Q3 2025), and $591.6 million (Q2 2025).